Stock Events

Rezolute 

$1.8
5
+$0.15+9.09% Friday 21:00

Statistics

Day High
1.95
Day Low
1.64
52W High
2.62
52W Low
0.72
Volume
274,694
Avg. Volume
443,100
Mkt Cap
71.33M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-0.38
-0.32
-0.25
-0.19
Expected EPS
-0.3275
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RZLT. It's not an investment recommendation.

Analyst Ratings

8.67$Average Price Target
The highest estimate is $14.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

About

Internet Software/Services
Technology Services
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Show more...
CEO
Nevan Elam
Employees
57
Country
US
ISIN
US76200L3096

Listings